Journal: International Journal of Clinical and Experimental Pathology

Article Title: Expression of PERK-eIF2α-ATF4 pathway signaling protein in the progression of hepatic fibrosis in rats

doi:

Figure Lengend Snippet: The expression of p-PERK, p-eIF2α, ATF4 protein in liver of rats (SABC, ×200).

Article Snippet: CCl 4 (pure; Chengdu Jinshan Chemical Reagents Co., Ltd., Chengdu, China); Phosphorylated protein kinase R-like ER kinase (PERK), eukaryotic translation initiator factor 2α (eIF2α), and activating transcription factor 4 (ATF4) antibody I (Beijing Biosynthesis Biotechnology Co., Ltd., Beijing, China); β-Actin antibody (Wuhan Boster Biological Technology Co., Ltd.); TRIzol kit (Invitrogen, USA); Reverse transcription kit (Fermentas, USA); 2× SYBR green I kits (Applied Biosystems, USA); the β-Actin and ATF4 primers were designed and synthesized by TaKaRa Bioengineering (Dalian) Co., Ltd.

Techniques: Expressing

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Expression of PERK-eIF2α-ATF4 pathway signaling protein in the progression of hepatic fibrosis in rats

doi:

Figure Lengend Snippet: The expressions of p-PERK, p-eIF2α and ATF4 proteins in the livers of the rats. C2: 2-week normal group; C4: 4-week normal group; C8: 8-week normal group; C12: 12-week normal group; M2: 2-week hepatic fibrosis group; M4: 4-week hepatic fibrosis group; M8: 8-week hepatic fibrosis group; M12: 12-week hepatic fibrosis group.

Article Snippet: CCl 4 (pure; Chengdu Jinshan Chemical Reagents Co., Ltd., Chengdu, China); Phosphorylated protein kinase R-like ER kinase (PERK), eukaryotic translation initiator factor 2α (eIF2α), and activating transcription factor 4 (ATF4) antibody I (Beijing Biosynthesis Biotechnology Co., Ltd., Beijing, China); β-Actin antibody (Wuhan Boster Biological Technology Co., Ltd.); TRIzol kit (Invitrogen, USA); Reverse transcription kit (Fermentas, USA); 2× SYBR green I kits (Applied Biosystems, USA); the β-Actin and ATF4 primers were designed and synthesized by TaKaRa Bioengineering (Dalian) Co., Ltd.

Techniques:

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Expression of PERK-eIF2α-ATF4 pathway signaling protein in the progression of hepatic fibrosis in rats

doi:

Figure Lengend Snippet: The expression of hepatic fibrosis p-PERK, p-eIF2α, ATF4 protein and ATF4 mRNA in each group (mean ± s, n=7)

Article Snippet: CCl 4 (pure; Chengdu Jinshan Chemical Reagents Co., Ltd., Chengdu, China); Phosphorylated protein kinase R-like ER kinase (PERK), eukaryotic translation initiator factor 2α (eIF2α), and activating transcription factor 4 (ATF4) antibody I (Beijing Biosynthesis Biotechnology Co., Ltd., Beijing, China); β-Actin antibody (Wuhan Boster Biological Technology Co., Ltd.); TRIzol kit (Invitrogen, USA); Reverse transcription kit (Fermentas, USA); 2× SYBR green I kits (Applied Biosystems, USA); the β-Actin and ATF4 primers were designed and synthesized by TaKaRa Bioengineering (Dalian) Co., Ltd.

Techniques: Expressing

Journal: Cells

Article Title: MiR-34b Regulates Muscle Growth and Development by Targeting SYISL

doi: 10.3390/cells14050379

Figure Lengend Snippet: All primers used in RT-qPCR.

Article Snippet: Antibodies that were used included MyoG (sc-12732; 1:200; Santa Cruz Biotechnology, Dallas, TX, USA), MyHC (sc-376157; 1:1000; Santa Cruz Biotechnology, Dallas, TX, USA), β-actin (sc-4777; 1:1000; Santa Cruz Biotechnology, Dallas, TX, USA), CDK6 (BA1513; 1:300; BOSTER, Wuhan, China), Ki67 (ab16667; 1:1000; Abcam, Cambridge, United Kingdom), p21 (BM4382; 1:200; BOSTER, Wuhan, China), and a secondary antibody (1:3000; Santa Cruz Biotechnology, Dallas, TX, USA).

Techniques: Sequencing

Journal: Cells

Article Title: MiR-34b Regulates Muscle Growth and Development by Targeting SYISL

doi: 10.3390/cells14050379

Figure Lengend Snippet: Effects of miR-34b on genes related to myoblast proliferation. ( A ) The inhibiting effect of miR-34b inhibitor is remarkable. Data were presented as mean ± SDs, n = 3. * p < 0.05. ( B ) RT-qPCR of proliferated C2C12 myoblasts showed that CDK6 and ki67 levels are significantly increased and p21 level is significantly decreased in miR-34b knockdown ( miR-34b inhibitor) group compared with the negative control (miR-NC) group. Data were presented as mean ± SDs, n = 3. * p < 0.05. ( C ) Western blotting of proliferated C2C12 myoblasts showed that CDK6 and ki67 protein levels are significantly increased and p21 protein level is significantly decreased in miR-34b knockdown ( miR-34b inhibitor) group compared with the negative control (miR-NC) group. Data were presented as mean ± SDs, n = 3. * p < 0.05. ( D ) Representative photograph of EdU staining in proliferating C2C12 myoblasts. Quantification of three independent experiments showed that cell proliferation is promoted after inhibiting miR-34b . Data were presented as mean ± SDs, n = 3 * p < 0.05. ( E ) The overexpression effect of miR-34b mimics is remarkable. Data were presented as mean ± SDs, n = 3. *** p < 0.001 ( F ) RT-qPCR of proliferated C2C12 myoblasts shows that CDK6 and ki67 levels are significantly decreased and p21 level is significantly increased in miR-34b overexpression ( miR-34b mimics) group compared with the negative control (miR-NC) group. Data were presented as mean ± SDs, n = 3. * p < 0.05. ( G ) Western blotting of proliferated C2C12 myoblasts showed that CDK6 and ki67 protein levels are significantly decreased and p21 protein level is significantly increased in miR-34b overexpression ( miR-34b mimics) group compared with the negative control (miR-NC) group. Data were presented as mean ± SDs, n = 3. * p < 0.05. ( H ) Representative photograph of EdU staining in proliferating C2C12 myoblasts. Quantification of three independent experiments showed that cell proliferation is inhibited after miR-34b overexpression. Data were presented as mean ± SDs, n = 3. * p < 0.05.

Article Snippet: Antibodies that were used included MyoG (sc-12732; 1:200; Santa Cruz Biotechnology, Dallas, TX, USA), MyHC (sc-376157; 1:1000; Santa Cruz Biotechnology, Dallas, TX, USA), β-actin (sc-4777; 1:1000; Santa Cruz Biotechnology, Dallas, TX, USA), CDK6 (BA1513; 1:300; BOSTER, Wuhan, China), Ki67 (ab16667; 1:1000; Abcam, Cambridge, United Kingdom), p21 (BM4382; 1:200; BOSTER, Wuhan, China), and a secondary antibody (1:3000; Santa Cruz Biotechnology, Dallas, TX, USA).

Techniques: Quantitative RT-PCR, Knockdown, Negative Control, Western Blot, Staining, Over Expression